Bevacizumab biosimilar (Betta/Mabworks)

贝伐珠单抗生物类似药（贝达/天广实）

Report date: 2022/03/10 16:09:00

Base Information

Drug NameBevacizumab biosimilar (Betta/Mabworks)
Drug Alias Name贝伐珠单抗生物仿制药（天广实生物）贝伐人源化单抗生物仿制药（天广实生物）贝伐单抗生物仿制药（天广实生物）贝伐赛珠单抗生物仿制药（天广实生物）重组抗人血管内皮生长因子人源化单抗（贝达/天广实） +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[8] 
Global Approved IndicationsCarcinoma, Non-Small-Cell LungColorectal Neoplasms
Approved Indications in ChinaCarcinoma, Non-Small-Cell LungColorectal Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2021/11/24
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesInstitute Of Basic Medicine, Chinese Academy Of Medical SciencesBeijing Mabworks Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBetta Pharmaceuticals Co LtdBetta
Inactive CompaniesBeijing Mabworks Biotech Co LtdInstitute Of Hygiene And Environmental Medicine Chinese Academy Of Military Medical Sciences
Active IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeL01XC07
Related LinksN/A